Vertex Pharmaceuticals' second quarter revenue of $3.33B beats estimates, driven by CF franchise and new product growth.

Vertex Pharmaceuticals reported second quarter 2026 revenue of $3.33 billion, up 12% year-over-year, beating analyst estimates. Non-GAAP diluted EPS was $4.73, also ahead of expectations. The company raised its full-year 2026 revenue guidance to a range of $13.1 billion to $13.2 billion.

Key Highlights

• Raised full-year 2026 revenue guidance to $13.1 billion - $13.2 billion, up from $12.95 billion - $13.1 billion previously.
• Revenue from new products CASGEVY and JOURNAVX grew to $76.4 million and $49.6 million respectively, showing strong sequential growth of 78% and 71%.
• The core Cystic Fibrosis (CF) franchise revenue grew 11% to $3.21 billion, fueled by the strong uptake of ALYFTREK, which generated $573.6 million in sales.